vaccines

The rate of disease onset or relapse of neuromyelitis optica spectrum disorder (NMOSD) after a SARS-CoV-2 infection — the virus that causes COVID-19 — is extremely low, at about 1 in 50 million, according to a worldwide review study. The occurrence of NMOSD was even lower, at 1 in…

The risk of neuromyelitis optica spectrum disorder (NMOSD) attacks following vaccination is low, and such attacks have not been found to be associated with any particular type of vaccine, according to a review study. Also, post-vaccine attacks tended to happen more frequently in men, patients negative for antibodies against…

Uplizna (inebilizumab) does not increase the risk of COVID-19 infection or reduce the levels of antibodies produced from prior childhood vaccines among people with neuromyelitis optica spectrum disorder (NMOSD). That’s according to two posterior analyses of data from the Phase 2/3 N-MOmentum clinical trial (NCT02200770) after the…

More than half of the people with rare diseases and their caregivers, asked in a survey, were undecided or less than willing to be vaccinated for COVID-19 if a vaccine was approved under emergency use authorization instead of the routine process, the EveryLife Foundation for Rare Disease reports. These findings…